AZD2014 and Weekly Paclitaxel in Squamous NSCLC
NCT02403895
Terminated
Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/04/2018
Locations: Research Site, Boston, Massachusetts +6 locations
Conditions: Squamous Non Small Cell Lung Cancer
Register for Updates
Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer
NCT02252796
Terminated
This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/25/2018
Locations: West Virginia University Hospitals Mary Babb Randolph Cancer Center, Morgantown, West Virginia
Conditions: Non-small Cell Lung Cancer
Register for Updates
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
NCT00055601
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of combination chemotherapy plus radiation therapy with or without surgery is more effective in treating bladder cancer. PURPOSE: Randomized phase II trial to study the effectiveness of two combination chemotherapy regimens and radiation therapy with or without radical c... Read More
Gender:
ALL
Ages:
120 years and below
Trial Updated:
05/15/2018
Locations: LDS Hospital, Salt Lake City, Utah +1 locations
Conditions: Bladder Cancer
Register for Updates
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
NCT01174238
Completed
This is a two arm prospective Phase II pilot trial designed to determine the optimal duration of break between axitinib and chemotherapy with carboplatin/paclitaxel in melanoma. In this study, 6 patients will be enrolled to Arm A, the FLT PET scan (3'deoxy-3'-18F-Fluorothymidine positron emission tomography scans)cohort. 30 patients will be enrolled to Arm B, the treatment-only cohort. 36 total patients will be enrolled. The treatment schedule will be the same in either cohort, with the exceptio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2018
Locations: Cutaneous Onocology Group at the Helen Dillar Family Comprehensive Cancer Center UCSF, San Francisco, California
Conditions: Melanoma
Register for Updates
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
NCT00955305
Terminated
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab (CPB) work when given with or without cixutumumab in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2018
Locations: The Medical Center of Aurora, Aurora, Colorado +164 locations
Conditions: Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer, Bronchioloalveolar Lung Carcinoma
Register for Updates
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
NCT01091428
Completed
This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Phase 1 and Phase 2 portions).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2018
Locations: Not set, Bronx, New York +3 locations
Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
Register for Updates
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
NCT00626405
Completed
RATIONALE: Drugs used in chemotherapy, such as temozolomide, paclitaxel albumin-stabilized nanoparticle formulation, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet k... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2018
Locations: Providence Cancer Center, Anchorage, Alaska +258 locations
Conditions: Melanoma (Skin)
Register for Updates
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
NCT02066103
Completed
Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed. This localized delivery is intended as an adjunct therapy and all subjects will receive standard of care oncology therapy as determined by their treating physicians.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2018
Locations: Johns Hopkins University, Baltimore, Maryland +2 locations
Conditions: Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer
Register for Updates
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
NCT00003054
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or persistent cancer of the uterus.
Gender:
FEMALE
Ages:
120 years and below
Trial Updated:
04/11/2018
Locations: University of Alabama Comprehensive Cancer Center, Birmingham, Alabama +64 locations
Conditions: Sarcoma
Register for Updates
A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
NCT00820768
Withdrawn
To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2018
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Solid Tumor
Register for Updates
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT01440998
Completed
This pilot phase I trial studies how well dasatinib works together with paclitaxel and carboplatin in treating patients with stage III, stage IV, or endometrial cancer that has come back after a period of improvement. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/04/2018
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Register for Updates
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
NCT00001426
Completed
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and continuous exposure is needed. This study will evaluate the combination of continuously administered CAI with three-weekly paclitaxel.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/04/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Ovarian Neoplasm
Register for Updates